RSC Advances
Paper
randomly divided into ve groups (n ¼ 6). The mice were treated
with different doses of compound 7g (10, 20, 40 mg kgꢂ1, dis-
Notes and references
solved in saline mixed with 5% Tween 80) and 5-Fu (25 mg kgꢂ1
,
1 F. E. Koehn and G. T. Carter, Nat. Rev. Drug Discovery, 2005,
4, 206–220.
2 M. S. Butler, J. Nat. Prod., 2004, 67, 2141–2153.
3 G. M. Cragg, P. G. Grothaus and D. J. Newman, Chem. Rev.,
2009, 109, 3012–3043.
4 A. Triantafyllou and I. Mylonis, Free Radical Biol. Med., 2008,
44, 657–670.
5 A. Scalbert, I. T. Johnson and M. Saltmarsh, Am. J. Clin. Nutr.,
2005, 81, 215S–217S.
6 M. Singh, M. Kaur and O. Silakari, Eur. J. Med. Chem., 2014,
84, 206–239.
7 E. Middleton Jr, C. Kandaswami and T. C. Theoharides,
Pharmacol. Rev., 2000, 52, 673–751.
dissolved in saline mixed with 5% Tween 80), saline (mixed with
5% Tween 80) via intraperitoneal injection on days 2, 5, 8, 11
and 14.
From day 6, tumor volumes were monitored every other day
by measuring two perpendicular diameters using a Vernier
caliper and calculated using the formula: volume ¼ 0.5 ꢃ
length ꢃ (width)2. Body weights were recorded every other day.
On day 18, the animals were sacriced and the tumor mass was
dissected, weighed, and photographed. The TIR was calculated
using the formula: TIR (%) ¼ (1 ꢂ Wt/Ws) ꢃ 100%, where Wt and
Ws represent the average tumor weight of the treatment and
saline groups, respectively.
8 B. H. Havsteen, Pharmacol. Ther., 2002, 96, 67–202.
9 H. Yoshiji, S. R. Harris and U. P. Thorgeirsson, Anticancer
Res., 2000, 20, 2249–2254.
Conclusion
10 L. Z. Liu, Y. Jing, L. L. Jiang, X. E. Jiang, Y. Jiang,
Y. Rojanasakul and B. H. Jiang, Biochem. Biophys. Res.
Commun., 2011, 413, 299–305.
11 Z. Y. Zhu, W. X. Wang, Z. Q. Wang, L. J. Chen, J. Y. Zhang,
X. C. Liu, S. P. Wu and Y. M. Zhang, Eur. J. Med. Chem.,
2014, 75, 297–300.
12 W. Huang, Q. Chen, W. C. Yang and G. F. Yang, Eur. J. Med.
Chem., 2013, 66, 161–170.
13 S. I. Grivennikov, F. R. Greten and M. Karin, Cell, 2010, 140,
883–899.
14 M. J. Thun, E. J. Jacobs and C. Patrono, Nat. Rev. Clin. Oncol.,
2012, 9, 259–267.
15 P. J. Loll, D. Picot and R. M. Garavito, Nat. Struct. Biol., 1995,
2, 637–643.
16 G. A. Spitz, C. M. Furtado, M. Sola-Penna and P. Zancan,
Biochem. Pharmacol., 2009, 77, 46–53.
In summary, a series of avonoid salicylate derivatives were
synthesized and these compounds were evaluated for their anti-
tumor activities. These compounds exhibited moderate to good
antiproliferative activity against MGC-803 cell lines and MFC
cell lines. An appropriate size of substituent group and the tri-
methoxybenzene had a certain inuence on the bioactivity of
the avonoid salicylate derivatives. Compound 2 and its salic-
ylate derivatives 7a–7g containing the trimethoxybenzene
exhibited greater antiproliferative activity. Among them,
compound 7g displayed the most potent antiproliferative
activity against MGC-803 cells and MFC cells with IC50 values of
11.05 ꢀ 1.58 mM and 13.73 ꢀ 2.04 mM, respectively. What's
more, the ow cytometry results showed that compound 7g
caused the cell cycle to be arrested in the G0/G1 phase and
induced apoptosis of MFC cells in a dose-dependent manner.
Furthermore, compound 7g also had good antitumor activity in
vivo. In summary, compound 7g can be recommended as a new,
potent anti-tumor candidate for further optimization and eval-
uation. Further study on the anti-tumor mechanism of
compound 7g is in progress.
17 G. R. Pettit, J. W. Lippert, D. L. Herald, E. Hamel and
R. K. Pettit, J. Nat. Prod., 2000, 63, 969–974.
18 G. J. Rustin, S. M. Galbraith, H. Anderson, M. Stratford,
L. K. Folkes, L. Sena, L. Gumbrell and P. M. Price, J. Clin.
Oncol., 2003, 21, 2815–2822.
19 G. R. Pettit, C. Temple, V. L. Narayanan, R. Varma,
M. J. Simpson, M. R. Boyd, G. A. Rener and N. B. Ansal,
Anti-Cancer Drug Des., 1995, 10, 299–309.
Conflict of interest
The authors declare that there are no conicts of interest.
20 G. R. Pettit and J. W. Lippert III, Anti-Cancer Drug Des., 2000,
5, 203–216.
21 G. Micheletti, M. Poli, P. Borsotti, M. Martinelli, B. Imberti,
G. Taraboletti and R. Giavazzi, Cancer Res., 2003, 63, 1534–
1537.
22 G. Kremmidiotis, A. F. Leske, T. C. Lavranos, D. Beaumont,
J. Gasic, A. Hall, M. O'Callaghan, C. A. Matthews and
B. Flynn, Mol. Cancer Ther., 2010, 9, 1562–1573.
23 J. Lee, S. J. Kim, H. Choi, Y. H. Kim, I. T. Lim, H.-m. Yang,
C. S. Lee, H. R. Kang, S. K. Ahn, S. K. Moon, D.-H. Kim,
S. Lee, N. S. Choi and K. J. Lee, Eur. J. Med. Chem., 2010,
53, 6337–6354.
Acknowledgements
This work was supported in part by the Construct Program of
the Key Discipline in Hunan Province and Hunan Province
Cooperative Innovation Center for Molecular Target New Drug
[Hunan Provincial Education Department document (Approval
number: 2014-405)]. The authors wish to thank the Department
of Laboratory Animal Science for support with the animal
experiments.
38178 | RSC Adv., 2017, 7, 38171–38178
This journal is © The Royal Society of Chemistry 2017